+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

PRINTER FRIENDLY

Remicade 2018 U.S. Promotional Audit Report

  • ID: 4616053
  • Report
  • July 2019
  • Region: United States
  • 28 pages
  • MD Details
1 of 3

FEATURED COMPANIES

The 5 Key Questions Addressed by this Report:
  • How many physicians were reached by Remicade through reportable promotional activity in 2018 and how does this compare to its peer set in the Ankylosing Spondylitis, Crohn's Disease, Psoriasis, Psoriatic Arthritis, Rheumatoid Arthritis, and Ulcerative Colitis markets?
  • What promotional mix was leveraged (e.g., sales rep detailing, physician education, and paid speaking) and what was the median spend for each type of activity?
  • How does J&J's depth of coverage vary within key specialties (e.g., Gastroenterology, Dermatology, Rheumatology, Internal Medicine, and Pediatric Medicine) and how does this compare to its peers and the overall set of rep-accessible physicians?
  • How often are physicians receiving paid meals for Remicade throughout the year (e.g., monthly, quarterly, annually)?
  • Who were the most frequent meal recipients and top paid speakers for Remicade in 2018?
Data Sources and Methodology:
  • Author leverages company-reported financial transaction data disclosed through CMS Open Payments. This data set captures all transfers of value (e.g., speaking fees, consulting fees, travel, education, and meals) made on behalf of a drug or device manufacturer to a physician. Currently, over 5 years of longitudinal data is available - covering payments to more than 1,000,000 U.S. healthcare professionals.
  • Over 12,200 paid interactions across 4,700 physicians made on behalf of Remicade were carefully examined to support our analysis. In addition, interaction data from 34 peer products (i.e. Actemra, Apriso, Canasa, Cimzia, Cosentyx, Delzicol, Enbrel, Enstilar, Entyvio, Humira, Ilaris, Ilumya, Impoyz, Inflectra, Kevzara, Kineret, Olux, Orencia, Otezla, Otrexup, Rasuvo, Rayos, Renflexis, Rituxan, Servino, Siliq, Simponi, Stelara, Taltz, Topicort, Tremfya, Uceris, Ultravate, and Xeljanz) was leveraged to provide benchmarking and market insights.
Note: Product cover images may vary from those shown
2 of 3

FEATURED COMPANIES

Overview:
  • Introduction
  • Sunshine Act and Open Payments Data
  • Transfer of Value
  • Author's Platform
Remicade - Peer Set:
  • Remicade Peer Set Selection
Remicade - Promotional Benchmarking:
  • Chart 1 Total Number of Physicians Reached by Specialty Type
  • Chart 2 Distribution of Physicians Reached by Specialty Type
  • Chart 3 Total Number of Payments by Type
  • Chart 4 Distribution of Payments by Type
  • Chart 5 Total Number of Payments / Week
  • Chart 6 Payment Value by Type
Remicade - Physician Coverage by Geography:
  • Chart 7 Gastroenterology
  • Chart 8 Dermatology
  • Chart 9 Rheumatology
  • Chart 10 Internal Medicine
  • Chart 11 Pediatric Medicine
Remicade - Meal Frequency:
  • Chart 12 Gastroenterology
  • Chart 13 Dermatology
  • Chart 14 Rheumatology
  • Chart 15 Internal Medicine
  • Chart 16 Pediatric Medicine
Remicade - Most Engaged Physicians:
  • Table 1: Top Physicians (By Total Number of Meals) in 2018
  • Table 2: Top Speakers (By Total Number of Speaking Events) in 2018
About:
  • Background
  • Service Lines
  • Contact
Note: Product cover images may vary from those shown
3 of 3

Loading
LOADING...

4 of 3
  • J&J
Note: Product cover images may vary from those shown
Adroll
adroll